FORM 1

COMMONWEALTH OF AUSTRALIA

PATENTS ACT 1952

APPLICATION FOR A STANDARD PATENT

Merck & Co., Inc., of 126 East Lincoln Avenue, Rahway, New Jersey, UNITED STATES OF AMERICA, hereby apply for the grant of a standard patent for an invention entitled:

Purification of Recombinant Hepatitis B Surface Antigen

which is described in the accompanying complete specification.

Details of basic application(s):-

Basic Applic. No: Country: Application Date:
023,347 UNITED STATES OF AMERICA 9 March 1987

The address for service is:-

Spruson & Ferguson
Patent Attorneys
Level 31 St Martins Tower
31 Market Street
Sydney New South Wales Australia

DATED this FOURTH day of MARCH 1988

Merck & Co., Inc.

By: M.J. Anderson

Registered Patent Attorney

TO: THE COMMISSIONER OF PATENTS
OUR REF: 48846
S/P CODE: 58190

5845/2
In support of the Convention Application made for a patent for an invention
entitled Purification of Recombinant Hepatitis B Surface Antigen

I, JAMES F. NAUGHTON
of MERCK & CO., Inc., 326 East Lincoln Avenue,
Rahway, New Jersey, United States of America
do solemnly and sincerely declare as follows:—

1. I am authorised by MERCK & CO., Inc.,
the applicant for the patent to make this declaration on its behalf.

2. The basic application as defined by Section 141 of the Act was made
in the United States of America on 9 March 1987
by William M. Hurni, Dennis J. Kubek, William J. Miller, Mark S. Rienstra,
and Edward M. Scolnick

3. William M. Hurni, Dennis J. Kubek, William J. Miller, Mark S. Rienstra,
and Edward M. Scolnick reside at 329 Evergreen Drive, North Wales,
Pennsylvania 19454; 1127 Vilsmeier Road, Lansdale, Pennsylvania 19446;
233 Old Church Road, North Wales, Pennsylvania 19454; 1519 Green Lane Road,
Lansdale, Pennsylvania 19446; and 811 Wickfield Road, Wynnewood,
Pennsylvania 19096, United States of America

The said Company is the assignee of the Inventor/s.

4. The basic application referred to in paragraph 2 of this Declaration
was the first application made in a Convention country in respect of
the invention the subject of the application.

Declared at Rahway, New Jersey, U.S.A.
this 30 day of December 1987.

James F. Naughton
Director-Administration
Off. of Sr. V.P. and Gen. Counsel

To:
The Commissioner of Patents,
Commonwealth of Australia.
1. A process for removing yeast-derived proteinaceous substances from a solution of a protein or polypeptide produced in a transformed yeast which comprises diafiltering the protein or polypeptide in the presence of a dissociating agent through a membrane having a molecular weight cutoff greater than about 50,000 daltons to about 1,000,000 daltons.

9. A process according to any one of Claims 1 to 8 wherein the protein or polypeptide is recombinant hepatitis B surface antigen.

12. Recombinant Hepatitis B surface antigen substantially free from contaminating yeast proteins.
The following statement is a full description of this invention, including the best method of performing it known to me/us.
PURIFICATION OF RECOMBINANT HEPATITIS B SURFACE ANTIGEN

ABSTRACT OF THE DISCLOSURE

Yeast proteins hydrophobically bonded to a desired protein or polypeptide produced in a transformed yeast are removed by treating the antigen with a chaotropic agent and concentrating the treated antigen in a hollow fiber capillary bundle having a molecular weight cutoff greater than 50,000 daltons but less than 1,000,000 daltons. The concentrated antigen is then diafiltered using a chaotropic agent to remove substantially all remaining yeast protein.
PURIFICATION OF RECOMBINANT HEPATITIS B SURFACE ANTIGEN

BACKGROUND OF THE INVENTION

In the production of recombinant hepatitis B surface antigen in yeast, a contaminating 60,000 dalton yeast protein associates with the hepatitis B surface antigen and is carried through the purification regimen of the surface antigen and appears in the final product. The contaminating yeast protein is closely associated with the surface antigen and cannot be removed from the 2,000,000 dalton surface antigen by conventional separation methods. The yeast impurity appears to be entrained within the interior of the surface antigen particle.

The presence of contaminating yeast protein in a vaccine product is undesirable.
OBJECTS OF THE INVENTION

It is, accordingly, an object of the present invention to provide an improved method for purifying polypeptides and proteins produced by a transformed yeast. Another object is to provide a method for removing yeast impurities from proteins and polypeptides produced in transformed yeast. These and other objects of the present invention will become apparent from the following description.

SUMMARY OF THE INVENTION

Yeast-derived proteins are removed from a polypeptide or a protein produced by a transformed yeast by diafiltering the polypeptide or protein with a dissociating agent across a membrane having a molecular weight cutoff greater than about 50,000 daltons but less than about 1,000,000 daltons, preferably from about 100,000 daltons to about 300,000 daltons.

DETAILED DESCRIPTION

The present invention relates to a method of removing contaminating yeast protein from a desired protein produced in a transformed yeast.

Typically the process of the present invention involves the fermentation of a yeast that has been transformed with a vector coding for a desired protein or polypeptide.

The antigen thus obtained is then purified by conventional purification methods which are customarily used for the isolation and purification of biologically active substances, such as cell
rupture, extraction of the ruptured cells, salting out with ammonium sulphate, gel filtration, ion exchange chromatography, fractionation with polyethyleneglycol, affinity chromatography, density gradient ultracentrifugation with sucrose and cesium chloride or sodium bromide, or the like. It is to be understood, of course, that while the invention has been illustrated with the use of transformed yeast encoding HBsAg, it is applicable to any other polypeptide or protein expressed by a transformed yeast when it is desired to remove extraneous yeast proteins from the expressed polypeptide or protein.

Following conventional purification the desired protein is treated according to the present invention to remove contaminating yeast protein. The treatment according to the present invention comprises difiltering the desired polypeptide or protein with a dissociating agent across a membrane having a molecular weight cutoff greater than about 50,000 daltons but less than about 1,000,000 daltons, preferably from about 100,000 daltons to about 300,000 daltons.

At the end of the fermentation, the yeast cells are broken to release the desired protein or polypeptide and the cells and cell debris are removed by centrifugation. The supernatant liquid is then treated to remove waste proteins, for example by concentration and diafiltration. The liquid containing the product is then adsorbed to aerosil (fused silica) and washed to remove contaminating proteins. The aerosil is eluted with a suitable buffer and the protein or polypeptide-containing
material is concentrated, diafiltered and optionally centrifuged. The supernatant liquid from the centrifugation is passed through a butylagarose column and adsorbed antigen is eluted in a suitable buffer. The material is then concentrated and loaded onto a Sepharose 6B column. Antigen-containing fractions from the Sepharose column are pooled, diluted to a desired protein concentration, and diluted with a chaotrope, leading to dissociation of yeast protein from the hepatitis B protein. Because the yeast protein becomes entrained in the desired yeast-produced protein particle, separation of the yeast protein is hindered and is not effected rapidly. Typically, the period of time to permit contaminating yeast proteins to dissociate is from about 6 hours to about 24 hours at room temperature although shorter times can be employed at higher temperatures. The mixture is then concentrated and diafiltered on a 100,000 molecular weight cutoff hollow fiber membrane using at least about five volumes of the dissociating agent as the diafiltration solution. The antigen is then diafiltered with at least about 15 volumes of phosphate buffered saline to remove the dissociating agent.

The transformed yeast can be prepared in known manner by introducing a gene encoding a desired polypeptide or protein into yeast cells which then express the encoded polypeptide or protein. For instance, the preparation of HBsAg antigen from the transformed yeast is described by Valenzuela et al., Nature 298:347 et seq. (1982). Another known method
for preparing a yeast-origin HBsAg is described by Miyanohara et al., Proc. Natl. Acad. Sci., USA, 80:1 et seq. (1983).

The dissociating agent may be a polarity-reducing agent such as dioxane or ethylene glycol, urea, guanidine hydrochloride, or chaotropic agents such as Cl⁻, I⁻, ClO₄⁻, CF₃COO⁻, SCN⁻, or CCl₃COO⁻. Specific examples of suitable chaotropic agents are sodium perchlorate, sodium trifluoroacetate, sodium trichloroacetate, and alkali metal thiocyanates, e.g., NaSCN, KSCN, and NH₄SCN.

The following examples illustrate the present invention without, however, limiting the same thereto.

EXAMPLE 1

A recombinant hepatitis B surface antigen preparation consisting of 8 L of purified hepatitis B surface antigen in PBS contains approximately 100 μg/ml of protein by Lowry protein assay. Typically, 5 percent of the protein measured consists of a contaminating 60,000 dalton yeast protein. To the above solution, 8 L of 6M KSCN in PBS is added. The resulting 16 L of solution contains 50 μg/ml of protein and has a concentration of 3M KSCN. This solution is incubated with stirring for 16 hours at 4°C. At the end of the incubation period the solution is concentrated to 4 L in a 100 K molecular weight cutoff hollow fiber bundle (Amicon H10 P100-20). The resulting concentrate contains approximately 200 μg/ml protein in 3M KSCN. The hollow fiber bundle unit is then switched from
concentration mode to diafiltration mode and the product is diafiltered using 20 L of 3M KSCN. The diafiltration mode removes the contaminating 60,000 dalton yeast protein that passes through the filter, from the 2,000,000 dalton hepatitis B surface antigen particle that is retained behind the filter. After completion of the diafiltration, the product is further diafiltered with 60 L of PBS to remove KSCN. The resulting product typically contains 100 µg/ml of protein in 6 L of which less than 1 percent of protein is yeast impurity as measured by HPLC.

EXAMPLE 2

A purified recombinant hepatitis B surface antigen containing Sepharose 6B effluent is made 3M with respect to KSCN by adding solid KSCN. It is then stored overnight at 4°C. Two ml of this material is mixed with 8 ml of 3M KSCN in PBS and then concentrated to 2 ml using an Amicon minicon concentrator with an XM300 membrane having a size exclusion of greater than 300,000 daltons. Then 5 ml of 3M KSCN is added and the total volume again reduced to 2 ml by pressure filtration. Another 5 ml of 3M KSCN is added and the total volume is reduced to 1 ml. This one ml of product is then dialyzed against PBS overnight at room temperature to remove KSCN. The solutions before and after treatment were analyzed by polyacrylamide gel and immunoblot and the treated solution was found to be free of yeast protein while the untreated solution exhibited a band which was recognized by antibody to yeast impurity.
EXAMPLE 3

Purified recombinant hepatitis B surface antigen is made 3M with respect to KSCN. A second sample was then made 2.5M with respect to KSCN and a third sample was made 2M with respect to KSCN by addition in each case of solid KSCN. Following incubation each of these samples was diafiltered against 5 volumes of KSCN having the same molarity with respect to KSCN using either an XM300 (300,000 M.W. cutoff) membrane or an XM100 (100,000 M.W. cutoff) membrane. After the KSCN treatment, all of the samples were dialyzed against PBS overnight at room temperature to remove KSCN. All of the samples were analyzed by polyacrylamide gel and immunoblot. All conditions of membrane size and KSCN concentration removed the yeast impurity from the hepatitis B surface antigen.
CLAIMS
WHAT IS CLAIMED IS:

The claims defining the invention are as follows:

1. A process for removing yeast-derived proteinaceous substances from a solution of a protein or polypeptide produced in a transformed yeast which comprises diafiltering the protein or polypeptide in the presence of a dissociating agent through a membrane having a molecular weight cutoff greater than about 50,000 daltons to about 1,000,000 daltons.

2. A process according to Claim 1 wherein the dissociating agent is a polarity reducing agent or a chaotropic agent.

3. A process according to Claim 2 wherein the polarity reducing agent is dioxane, ethylene glycol, urea or guanidine hydrochloride.

4. A process according to Claim 2 wherein the chaotropic agent is \( \text{CCl}_3\text{COO}^- \), \( \text{CF}_3\text{COO}^- \), \( \text{Cl}^- \), \( \text{ClO}_4^- \), \( \text{I}^- \) or \( \text{SCN}^- \).

5. A process according to Claim 1 wherein the membrane has a molecular weight cutoff of from about 100,000 daltons to about 300,000 daltons.

6. A process according to Claim 1 wherein the solution of the protein or polypeptide is incubated in the presence of the dissociation agent before diafiltering.
7. A process according to Claim 1 wherein the solution of the protein or polypeptide is concentrated before diafiltering.
8. A process according to Claim 1 wherein the solution of the protein or polypeptide is removed following diafiltering.
9. A process according to any one of Claims 1 to 8 wherein the protein or polypeptide is recombinant hepatitis B surface antigen.
10. A process for removing yeast-derived proteinaceous substances from a solution of a protein or polypeptide produced in a transformed yeast substantially as hereinbefore described with reference to any one of the Examples.
11. The product of the process of any one of claims 1 to 10.
12. Recombinant Hepatitis B surface antigen substantially free from contaminating yeast proteins.

DATED this TWENTY-SEVENTH day of JANUARY 1988
MERCK & CO. INC.

Patent Attorneys for the Applicant
SPRUSON & FERGUSON